company background image
ACET

Adicet Bio NasdaqGM:ACET Stock Report

Last Price

US$8.49

Market Cap

US$363.8m

7D

-7.0%

1Y

-43.6%

Updated

08 Feb, 2023

Data

Company Financials +

ACET Stock Overview

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases.

ACET fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Adicet Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adicet Bio
Historical stock prices
Current Share PriceUS$8.49
52 Week HighUS$21.87
52 Week LowUS$7.42
Beta1.99
1 Month Change11.27%
3 Month Change-59.14%
1 Year Change-43.59%
3 Year Changen/a
5 Year Changen/a
Change since IPO-44.87%

Recent News & Updates

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Recent updates

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20
Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16
Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18
We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management

Dec 28

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Dec 16
Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

ACETUS BiotechsUS Market
7D-7.0%-0.5%1.6%
1Y-43.6%2.9%-10.8%

Return vs Industry: ACET underperformed the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: ACET underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is ACET's price volatile compared to industry and market?
ACET volatility
ACET Average Weekly Movement15.2%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: ACET is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ACET's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a86Chen Schorhttps://www.adicetbio.com

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma.

Adicet Bio, Inc. Fundamentals Summary

How do Adicet Bio's earnings and revenue compare to its market cap?
ACET fundamental statistics
Market CapUS$363.81m
Earnings (TTM)-US$55.73m
Revenue (TTM)US$30.46m

11.9x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACET income statement (TTM)
RevenueUS$30.46m
Cost of RevenueUS$0
Gross ProfitUS$30.46m
Other ExpensesUS$86.19m
Earnings-US$55.73m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.30
Gross Margin100.00%
Net Profit Margin-182.97%
Debt/Equity Ratio0%

How did ACET perform over the long term?

See historical performance and comparison